GNTA vs. AVRO, CDTX, LENZ, IKNA, ALGS, TSBX, TARA, INAB, ENTX, and ATRA
Should you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include AVROBIO (AVRO), Cidara Therapeutics (CDTX), LENZ Therapeutics (LENZ), Ikena Oncology (IKNA), Aligos Therapeutics (ALGS), Turnstone Biologics (TSBX), Protara Therapeutics (TARA), IN8bio (INAB), Entera Bio (ENTX), and Atara Biotherapeutics (ATRA). These companies are all part of the "biological products, except diagnostic" industry.
Genenta Science (NASDAQ:GNTA) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.
15.1% of Genenta Science shares are held by institutional investors. Comparatively, 62.6% of AVROBIO shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 9.2% of AVROBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Genenta Science currently has a consensus price target of $25.00, suggesting a potential upside of 657.58%. AVROBIO has a consensus price target of $2.00, suggesting a potential upside of 43.88%. Given Genenta Science's stronger consensus rating and higher probable upside, analysts clearly believe Genenta Science is more favorable than AVROBIO.
In the previous week, AVROBIO had 5 more articles in the media than Genenta Science. MarketBeat recorded 7 mentions for AVROBIO and 2 mentions for Genenta Science. AVROBIO's average media sentiment score of 1.13 beat Genenta Science's score of 0.00 indicating that AVROBIO is being referred to more favorably in the news media.
Genenta Science has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
Genenta Science's return on equity of 0.00% beat AVROBIO's return on equity.
AVROBIO received 166 more outperform votes than Genenta Science when rated by MarketBeat users. However, 85.71% of users gave Genenta Science an outperform vote while only 66.93% of users gave AVROBIO an outperform vote.
Summary
Genenta Science beats AVROBIO on 7 of the 13 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genenta Science Competitors List
Related Companies and Tools
